Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Insights on Key Data From ASH 2020 on Myelodysplastic Syndromes and Myeloproliferative Neoplasms

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, PhD, discuss new data and studies in MDS and MPNs presented at ASH 2020.
Amy E. DeZern, MD, MHS
Srdan Verstovsek, MD, PhD
Released: February 5, 2021

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:

  • 3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 study
  • A post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients
  • 5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV study
  • Phase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependent
  • Analysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.


Amy E. DeZern, MD, MHS
Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Srdan Verstovsek, MD, PhD
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Downloadable slideset on the latest clinical data on the management of endometrial cancer, from Clinical Care Options (CCO)

person default Linda R. Duska, MD, MPH Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

Short downloadable slideset from Clinical Care Options (CCO) on managing HR+/HER2- early breast cancer

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.